bd has to realize that it needs to trim at the
top. until this is addressed the worker moral and
production will remain lower than it could be. bd is a
pretty good company but its management does not tap the
resources available to it. it is too hung up on the notion
that unless you have a bs degree you don't know
anything. the workers see what the problems are,but
management is slow to learn.due to this the stock price will
be slow to recover
BD's insulin syringe has been the ultimate Golden
Goose, delivering huge profits from the early 1980's
when Ralph Larsen (yes, that Ralph Larsen) convinced
Jack Howe to invest behind this gold mine. He built a
focused franchise and truly differentiated the offering.
Unfortunately for BD and its Diabetes Business, the goose only
layed one egg-the insulin syringe. They have never been
able to develop and launch new products or services.
In the mid 1980's they dropped the ball on a blood
glucose business three months before launch; they ignored
Novo's overtures on insulin pens, and they butchered an
insulin pump business that was sucessfull in Europe. Why
all these fiascos? Two reasons: One, BD is, plain and
simply, lousy at developing new products. Two:
management. Upper management leaves the same people in their
jobs despite their record of failure.( Who wants to
bet that the person behind the recent blood glucose
disaster has his/her fingerprints on several other
"beauts".) This is surely to protect their own jobs because
using performance-basd criteria would cost upper
management their jobs.
This latest reorganization will
shuffle the deck to cut some costs at the expense of one
of their most profitable businesses. Starving the
goose is not a long term strategy.
Our only hope is
that Castellini is looking for a buyout partner
(Tyco??) to increase the value of all his options before
he retires and moves back to Italy. We can't depend
on the new CEO to do this, because he is probably
too concerned with feathering his nest. Good
investing to all.
Even if you tell top management about dumb
decisions being made (like wrong head count cuts,
mis-management, bad conduct, unprofessional behaviour on senior
level) they all protect eachother anyhow... Maybe the
time has come to hire a crisis manager....
When showing me how to self-inject, my doctor
told me "don't worry, you won't have to be doing this
long, as everyone will be inhaling insulin by the end
of next year." What effect will this have on BDX? I
don't have any problems with its syringes (in fact
they're great!) and I think they must have a huge, huge
market share (haven't met anyone who uses anything else)
but the product, for diabetics anyway, may become
obsolete pretty fast. But I assume diabetic syringes are a
pretty small part of BDX's revenue?
All of your positive comments, such as those of
bdworker. I'm still a buyer...in fact my DRIP now buys MORE
than it did when I got in a year ago at around 42. I
know the history of BDX is too good to ignore or to
stay this low very long. I'm in for the long run,
although, like everyone, I too like some short term growth.
Thank-you for this information. It is
spelled out right in the BDX Brochure. Every 5 days.
My current DRiP/DSPPs are BDX, PFE. Both started
this year. Loading up on PFE as well.
in order of priority is JNJ, WLA, SGP,
Obviously this is a health sector portfolio. It's
interesting to me. With this area generally beaten down by
all kinds of circumstantial events, the long term
buy/hold investor should do well.
...would be very welcome right now.
news for us Longs: At least the dividend yield
growing every day. Ha ha ha!!
I'm still buying a
few more shares every Thursday. Gotta
-Scott, BDX DRiPper